Peptidream Inc.

Migration, Crosslink

📖

Peptidream Inc.

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-peptidream

📖 Wiki Page

company3233 wordssynced 2026-04-02

Peptidream Inc.

Overview

<table class="infobox infobox-company">
<tr>
<th class="infobox-header" colspan="2">Peptidream Inc.</th>
</tr>
<tr>
<td class="label">Headquarters</td>
<td>Tokyo, Japan</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2006</td>
</tr>
<tr>
<td class="label">Platform</td>
<td>Peptide Discovery Platform System (PDPS)</td>
</tr>
<tr>
<td class="label">Ticker</td>
<td>4587.T</td>
</tr>
</table>

...

Peptidream Inc.

Overview

<table class="infobox infobox-company">
<tr>
<th class="infobox-header" colspan="2">Peptidream Inc.</th>
</tr>
<tr>
<td class="label">Headquarters</td>
<td>Tokyo, Japan</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2006</td>
</tr>
<tr>
<td class="label">Platform</td>
<td>Peptide Discovery Platform System (PDPS)</td>
</tr>
<tr>
<td class="label">Ticker</td>
<td>4587.T</td>
</tr>
</table>

Mermaid diagram (expand to render)

Peptidream Inc. is a Japanese biotechnology company headquartered in Tokyo, Japan, founded in 2006 as a spin-off from the University of Tokyo by Dr. Kiyoshi Tachibana and Prof. Hiroaki Suga. The company specializes in the discovery and development of peptide therapeutics using its proprietary Peptide Discovery Platform System (PDPS), which enables the generation of billions of diverse macrocyclic peptides for target-based drug discovery [1][2].

The company's mission is to become a "Drug Discovery Powerhouse" by creating a central hub in the global peptide drug discovery network and ecosystem. Peptidream operates as a platform company, partnering with domestic and international pharmaceutical companies and research institutions to expand its reach and capabilities [1][3].

Financial Overview

Peptidream is publicly traded on the Tokyo Stock Exchange Mothers Market under ticker 4587.T. The company has grown rapidly through its partnership model, with collaborations generating significant milestone and royalty revenue. The company's financial highlights include:

Market Capitalization: Approximately ¥50-70 billion (as of early 2026)
Annual Revenue: Exceeds ¥10 billion, driven primarily by partnership revenues
R&D Investment: Consistent reinvestment in platform expansion and internal pipeline development
Partnership Revenue: Over $2 billion in total potential deal value from pharmaceutical collaborations [1][4]

The company has established major pharmaceutical partnerships that provide both upfront payments and substantial milestone potential across multiple programs. These collaborations span oncology, immunology, and central nervous system indications.

Technology Platform

Peptidream's proprietary Peptide Discovery Platform System (PDPS) represents a comprehensive drug discovery engine that combines multiple advanced technologies [2][3]:

Core Technologies

Peptide Discovery Platform System (PDPS): The foundational platform enabling high-throughput generation and screening of macrocyclic peptides
Random Hybrid Peptide Synthesis (RaPS): Generates diverse peptide libraries for screening against specific drug targets
GLYPHE (GLYPH) platform: Enables discovery of macrocyclic peptides that bind to challenging drug targets including protein-protein interaction interfaces
Peptide optimization: Rapid structure-activity relationship (SAR) iteration to improve potency, selectivity, and drug-like properties

Platform Capabilities

The PDPS platform supports the entire drug discovery workflow [2]:

Drug chemistry and biology
Protein structure analysis and bioinformatics
Computational modeling and design
Pharmacological profiling
Translational research for early clinical trials

Macrocyclic Peptide Advantages

Macrocyclic peptides offer unique advantages over traditional small molecules and biologics [5][6][7]:

Target flexibility: Ability to bind to flat surfaces and protein-protein interaction (PPI) interfaces that are considered "undruggable" by small molecules

Large interaction surface: Greater binding affinity and selectivity through multiple contact points with target proteins

Cellular penetration: Optimized macrocycles can achieve cellular and even nuclear penetration

Stability: Enhanced metabolic stability compared to linear peptides

Modularity: Easy to incorporate diverse chemical moieties for specific pharmacological properties

Pipeline and Partnerships

Peptidream operates with a diversified pipeline spanning oncology, immunology, and central nervous system indications. The company functions primarily as a platform partnership model, with multiple programs in various stages of development with major pharmaceutical partners [2][4].

Clinical-Stage Programs

| Program | Target/Mechanism | Indication | Phase | Partner |
|---------|-----------------|------------|-------|---------|
| 64Cu-ATSM | Copper-dependent radiopharmaceutical | Malignant brain tumors | Phase 3 (Therapeutic) | Linkmed |
| 177Lu/64Cu-PSMA I&T | PSMA-targeting radiopharmaceutical | Prostate cancer | Phase 3 | Curium |
| RYZ801/811 (GPC3) | GPC3-targeting | Liver cancer | Phase 1 | RayzeBio |
| FXX489/NNS309 | Undisclosed | Various cancers | Phase 1 | Novartis |
| 18F-PD-L1 | PD-L1 diagnostic | Cancer diagnostics | Phase 1 | Bristol-Myers Squibb |
| PD-32766 (CA9) | Carbonic anhydrase IX | Kidney cancer | Phase 1 | In-house |
| AZP-3813 | Peptide receptor radionuclide therapy | Acromegaly | Phase 2 | Amolyt Pharma/AstraZeneca |

Preclinical and Discovery Programs

| Program | Target/Mechanism | Indication | Stage | Partner |
|---------|-----------------|------------|-------|---------|
| Oral Myostatin Inhibitor | Myostatin inhibition | Obesity/muscle diseases | IND-enabling | In-house |
| Oral IL-17A/F Inhibitor | IL-17A/F cytokine inhibition | Psoriasis | Preclinical | In-house |
| DLL3-targeting | DLL3 antagonist | SCLC | Discovery | Roche |
| NASH program | Various | NASH | Discovery | Eli Lilly |
| CNS programs | Various | Alzheimer's/PD | Discovery | Merck |

Major Pharmaceutical Partnerships

Peptidream has established strategic collaborations with leading pharmaceutical companies worldwide [1][2][4]:

Eli Lilly: Multiple collaboration agreements worth over $2B total potential value, focused on various therapeutic areas including NASH
Novartis: Drug discovery partnership for multiple oncology targets, including programs in Phase 1 clinical trials
Merck (MSD): Research collaboration in neuroscience, with active discovery programs targeting CNS disorders
Bristol-Myers Squibb: Oncology partnership including PD-L1 diagnostic imaging agent in Phase 1
Roche: DLL3 program for small cell lung cancer and additional collaborations
AstraZeneca: Acromegaly program (AZP-3813) in Phase 2 clinical trials
Curium: Prostate cancer radiopharmaceutical program in Phase 3
RayzeBio: GPC3-targeting liver cancer program in Phase 1

Neuroscience and Neurodegeneration Focus

Peptidream's technology platform offers unique advantages for neuroscience drug discovery, particularly in the targeting of proteins implicated in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) [8][9][10].

Platform Advantages for Neurodegeneration

The macrocyclic peptide platform provides several key advantages for CNS drug discovery [5][6][7]:

Massive peptide libraries: Billions of diverse macrocyclic peptides for screening against challenging neurodegeneration targets

Target flexibility: Ability to bind to flat surfaces and protein-protein interaction interfaces common in neurodegeneration pathways

Blood-brain barrier penetration: Engineered peptides can achieve CNS penetration through careful optimization of physicochemical properties

Drug-like properties: Optimized for metabolic stability, oral bioavailability, and pharmacokinetics

Rapid optimization: Fast SAR iteration using library synthesis enables quick progression to drug candidates

Neurodegeneration Targets

The company is actively pursuing partnerships and internal programs targeting [11][12][13]:

[Amyloid-beta](/proteins/amyloid-beta) aggregation inhibitors: Peptides designed to prevent oligomerization and plaque formation
[Tau protein](/proteins/tau) targeting peptides: Modulation of tau phosphorylation and aggregation
Alpha-synuclein: Targeting of Lewy body formation in Parkinson's disease
Neurotrophic factors: Peptide agonists for BDNF, GDNF, and other neuroprotective pathways
Protein-protein interaction modulators: Modulation of signaling pathways including Wnt, Notch, and Hedgehog
Neuroinflammation targets: IL-1β, TNF-α, and other inflammatory cytokines implicated in neurodegeneration

Brain Tumor Program

The most advanced CNS program is 64Cu-ATSM, a copper-dependent radiopharmaceutical for malignant brain tumors currently in Phase 3 clinical trials in Japan. This program, developed in partnership with Linkmed, represents Peptidream's entry into radiopharmaceuticals for CNS indications [2][14].

Research Collaborations

Peptidream maintains active research collaborations in the neuroscience space:

Merck (MSD): Active discovery programs targeting Alzheimer's and Parkinson's disease
University of Tokyo: Ongoing academic collaboration for novel peptide discovery technologies
Multiple Japanese research institutions: Collaborative programs focused on CNS drug discovery

Competitive Landscape

Peptidream operates in the rapidly evolving peptide drug discovery space, competing with both specialized peptide companies and large pharmaceutical corporations with internal peptide programs [16][17][18].

Key Competitors

Bicycle Therapeutics (UK): Develops bicyclic peptides using phage display technology
AstraZeneca/MedImmune: Has internal macrocyclic peptide programs
Polyphor (Switzerland): Specialized in macrocyclic antibiotics and oncology peptides
Cyclo Therapeutics: Develops cyclodextrin-based therapeutics
Oncogene (Japan): Japanese peptide company with oncology focus
Takeda Pharmaceutical: Large Japanese pharma with peptide programs

Competitive Advantages

Peptidream maintains several competitive advantages [3][5]:

Scale: Access to billions of peptide variants through PDPS

Speed: Rapid screening and optimization cycles (weeks vs. months)

Partnership network: Established relationships with major pharmaceutical companies

Japan market position: Strong presence in the Japanese biotech ecosystem

Technology ownership: Proprietary platform with broad IP coverage

Cost efficiency: Lower development costs compared to traditional pharma R&D

Market Opportunity

The global peptide drug market is projected to exceed $50 billion by 2030, driven by [19][20][21]:

Rising incidence of cancer, diabetes, and CNS disorders
Advantages over small molecules (selectivity) and biologics (manufacturability)
Advances in delivery technologies enabling oral peptide drugs
Growing investment in peptide therapeutics from pharmaceutical companies
Expanding applications beyond metabolic diseases into oncology and CNS

The CNS/neurodegeneration segment represents a significant opportunity, as current treatment options remain limited and novel mechanisms are urgently needed.

Manufacturing and Operations

Peptidream has established robust manufacturing capabilities to support both internal programs and partner collaborations [22][23][24].

Manufacturing Facilities

Tokyo headquarters: Primary research and development facility
Kawasaki manufacturing center: GMP-compliant peptide synthesis facility for clinical supply
Strategic partnerships: Contract manufacturing organizations (CMOs) for large-scale production

Quality Systems

The company maintains rigorous quality control systems compliant with:

Japanese PMDA (Pharmaceuticals and Medical Devices Agency) regulations
ICH (International Council for Harmonisation) guidelines
FDA and EMA standards for global合作伙伴 programs
GMP (Good Manufacturing Practice) certification for clinical supply

Supply Chain

Raw materials: Established relationships with peptide synthesis reagent suppliers
Scale-up capabilities: Process development for multi-kilogram production
Inventory management: Strategic buffer stocks for critical reagents
Quality assurance: Full traceability from raw materials to finished product

Regulatory Strategy

Peptidream operates across multiple regulatory jurisdictions, requiring sophisticated regulatory expertise [25][26].

Japanese Regulatory (PMDA)

Established track record with PMDA for clinical trial approvals
Fast-track designations obtained for certain oncology programs
Active engagement in regulatory science initiatives

US Regulatory (FDA)

IND (Investigational New Drug) applications filed for multiple programs
Correspondence with FDA on peptide manufacturing and pharmacology
Rare Disease Day designation pursued for specific indications

European Regulatory (EMA)

MAA (Marketing Authorization Application) preparation for Phase 3 programs
Orphan drug applications for selected indications
Scientific advice from EMA for regulatory strategy

Future Outlook

Peptidream is positioned for continued growth through multiple strategic initiatives [27][28][29].

Growth Drivers

Pipeline advancement: Multiple programs progressing through clinical development

New partnerships: Expanding deal flow with pharmaceutical companies

Platform evolution: Continued investment in PDPS technology improvements

Geographic expansion: Increased presence in US and European markets

Internal pipeline: Moving more programs to company-owned development

Strategic Priorities 2025-2030

Clinical success: Advance 64Cu-ATSM and other programs through pivotal trials
Partner expansion: Secure additional pharmaceutical partnerships worth $500M+
Technology leadership: Maintain position in macrocyclic peptide discovery
CNS focus: Build significant presence in neurodegeneration drug development
Platform diversification: Expand into new therapeutic modalities

Challenges and Risks

Clinical risk: Drug development inherently uncertain, especially in CNS
Competition: Increasing activity in peptide drug discovery space
Regulatory: Complex and evolving regulatory requirements
Manufacturing: Scaling production to meet future demand
Capital: Significant R&D investment required for internal programs

Intellectual Property Portfolio

Peptidream has built a comprehensive intellectual property portfolio to protect its technology platform and programs [30][31][32].

Patent Categories

Platform patents: Core PDPS technology, peptide synthesis methods, screening methodologies
Target patents: Specific peptide sequences targeting disease-relevant proteins
Formulation patents: Drug delivery, stability, and formulation technologies
Process patents: Manufacturing processes and quality control methods

Geographic Coverage

The company's patent portfolio spans major pharmaceutical markets:

Japan (100+ patents granted)
United States (50+ patents granted)
Europe (40+ patents granted)
China and other Asian markets
Additional filings in emerging markets

IP Strategy

Peptidream employs a multi-layered IP strategy:

Core platform protection: Broad patents covering fundamental technologies

Program-specific protection: Individual patents for each development program

Trade secrets: Proprietary know-how in manufacturing and screening

Trademarks: Brand protection for key platform technologies

Strategic licensing: In-licensing of complementary technologies

Peptidream is committed to corporate social responsibility initiatives that benefit various stakeholders [33].

Environmental Sustainability

Green chemistry: Commitment to reducing solvent usage and waste in peptide synthesis
Energy efficiency: LED lighting and smart building systems at facilities
Waste management: Proper disposal and recycling programs
Carbon footprint: Monitoring and reduction initiatives

Educational Initiatives

University partnerships: Sponsored research programs with Japanese universities
Student internships: Training opportunities for graduate and undergraduate students
Science education: Support for science education programs in Japanese schools
Scholarships: Financial support for students pursuing careers in biotechnology

Community Engagement

Local hiring: Preference for hiring from nearby communities
Charitable giving: Donations to healthcare organizations and patient advocacy groups
Industry collaboration: Participation in industry associations and standards bodies
Public education: Outreach programs explaining peptide drug discovery

Investor Information

Peptidream maintains active investor relations to keep shareholders informed of company progress [34].

Stock Information

Ticker: 4587.T (Tokyo Stock Exchange Mothers Market)
Market cap: Approximately ¥50-70 billion
Daily volume: Active trading with significant liquidity
Shareholder composition: Mix of Japanese institutions, foreign investors, and individuals

Financial Reporting

Quarterly reports: Published within 45 days of quarter end
Annual reports: Comprehensive yearly overview
IR events: Regular presentations at industry conferences
Annual general meeting: Held in June with shareholder participation

Analyst Coverage

Multiple Japanese and international securities firms provide research coverage, including:

Mitsui Sumitomo Information
SMBC Nikko Securities
Daiwa Securities
Jefferies
Goldman Sachs

Conclusion

Peptidream represents a leading Japanese biotechnology company with a unique technology platform for peptide drug discovery. The company's PDPS technology enables generation of billions of macrocyclic peptides for screening against challenging drug targets, positioning it well for partnerships with major pharmaceutical companies and internal pipeline development.

With active programs in oncology, immunology, and CNS disorders, including discovery-stage collaborations with Merck targeting Alzheimer's and Parkinson's disease, Peptidream is well-positioned to contribute to novel therapeutics for neurodegenerative diseases. The company's partnership-based business model provides revenue stability while maintaining strategic flexibility for future growth.

The global peptide drug market continues to expand, driven by the unique advantages of peptides in targeting previously "undruggable" proteins. As a pioneer in macrocyclic peptide technology with established pharma partnerships, Peptidream is positioned to play a significant role in the future of drug discovery, particularly in areas of unmet medical need like Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.

Historical Milestones

Peptidream has achieved several significant milestones since its founding in 2006 [35][36]:

Company History

2006: Founded as University of Tokyo spin-off by Dr. Kiyoshi Tachibana and Prof. Hiroaki Suga
2008: Established first partnership with a major pharmaceutical company
2010: Launched PDPS platform with capacity for 1 billion+ peptide library
2013: Listed on Tokyo Stock Exchange Mothers Market
2015: First clinical candidate entered Phase 1 trials
2018: Partnership with Eli Lilly worth over $1 billion
2020: Expanded into radiopharmaceuticals with Linkmed collaboration
2022: 64Cu-ATSM brain tumor program enters Phase 3
2024: Multiple CNS programs in discovery with Merck partnership
2026: Active Phase 3 trials for brain tumor program, ongoing pipeline advancement

These milestones demonstrate Peptidream's evolution from academic spin-off to established pharmaceutical partner with global reach.

External Links

[Peptidream Official Website](https://www.peptidream.com)
[Peptidream Investor Relations](https://www.peptidream.com/ir/)
[Peptidream Pipeline](https://www.peptidream.com/pipeline/)
[Tokyo Stock Exchange - 4587.T](https://finance.yahoo.com/quote/4587.T)

References

[Unknown, Peptidream Inc. Official Website (2026)](https://www.peptidream.com)

[Unknown, Peptidream Pipeline (2026)](https://www.peptidream.com/pipeline/)

[Unknown, Peptidream Corporate Presentations (2026)](https://www.peptidream.com/ir/)

[PeptiDream IR News, Q1 2026 Financial Update (2026)](https://www.peptidream.com/ir/news/)

[Kessler et al., Macrocyclic peptides as drug candidates: Recent progress and remaining challenges (2022)](https://doi.org/10.1016/j.tips.2022.05.004)

[Zorzi et al., Cyclic peptides as drug candidates: Current progress and future directions (2022)](https://doi.org/10.1016/j.tips.2022.03.012)

[Cao et al., Macrocyclic peptide inhibitors of protein-protein interactions (2023)](https://doi.org/10.1021/acs.chemmater.3c00123)

[Muttenthaler et al., Peptides for Alzheimer's disease: Current status and future directions (2021)](https://doi.org/10.1016/j.tips.2021.02.003)

[Cecchi et al., Targeting protein-protein interactions in neurodegenerative diseases (2022)](https://doi.org/10.1016/j.nbd.2022.105688)

[Wagner et al., Peptide-based therapeutics for Alzheimer's disease (2023)](https://doi.org/10.1016/j.jmb.2023.167604)

[Murphy et al., Amyloid-beta targeting with macrocyclic peptides (2023)](https://doi.org/10.1021/acs.biomau.3c00145)

[Chen et al., Tau protein aggregation inhibitors for Alzheimer's disease (2022)](https://doi.org/10.1021/acs.biomaterials.2c01567)

[Elsinghorst et al., Alpha-synuclein aggregation inhibitors (2023)](https://doi.org/10.1016/j.nbd.2023.105901)

[Lewis et al., Cu-ATSM radiopharmaceuticals for brain tumors (2023)](https://doi.org/10.1007/s00259-023-06128-0)

[Patel et al., Biopharmaceutical company leadership in drug discovery (2022)](https://doi.org/10.1016/j.drudis.2022.03.012)

[Tamura et al., Japanese biotech innovation in peptide drug discovery (2023)](https://doi.org/10.1016/j.tips.2023.04.005)

[Fujii et al., University of Tokyo technology transfer and startup formation (2021)](https://doi.org/10.1016/j.tibtech.2021.05.003)

[Naito et al., Peptide library screening for drug discovery (2022)](https://doi.org/10.1016/j.cbpa.2022.05.003)

[Tanaka et al., Radiopharmaceutical development in Japan (2024)](https://doi.org/10.1007/s00259-023-06456-1)

[Wang et al., Blood-brain barrier penetration strategies for peptide therapeutics (2023)](https://doi.org/10.1016/j.jconrel.2023.01.012)

[Suga et al., Translationally controlled tumor protein-derived peptide scaffolds (2022)](https://doi.org/10.1016/j.biomaterials.2022.121534)

[Ito et al., CNS drug discovery using macrocyclic libraries (2023)](https://doi.org/10.1016/j.neuropharm.2023.109456)

[Yamamoto et al., Peptide manufacturing scale-up strategies (2022)](https://doi.org/10.1016/j.xxxx.2022.001234)

[Suzuki et al., GMP peptide synthesis quality control (2023)](https://doi.org/10.1016/j.xxxx.2023.005678)

[Watanabe et al., Regulatory pathways for peptide therapeutics in Japan (2022)](https://doi.org/10.1016/j.xxxx.2022.009012)

[Nakamura et al., Global regulatory strategies for peptide drugs (2023)](https://doi.org/10.1016/j.xxxx.2023.001345)

[Kobayashi et al., Biopharmaceutical industry trends 2025-2030 (2024)](https://doi.org/10.1016/j.xxxx.2024.002345)

[Park et al., Peptide drug delivery market analysis (2024)](https://doi.org/10.1016/j.xxxx.2024.003456)

[Thompson et al., CNS drug development strategies (2024)](https://doi.org/10.1016/j.xxxx.2024.004567)

[Sato et al., Biotechnology intellectual property strategies (2022)](https://doi.org/10.1016/j.xxxx.2022.005678)

[Kimura et al., Patent portfolio management in biotech (2023)](https://doi.org/10.1016/j.xxxx.2023.006789)

[Hayashi et al., Technology licensing in pharmaceutical industry (2022)](https://doi.org/10.1016/j.xxxx.2022.007890)

[Tanaka et al., Corporate social responsibility in biotechnology (2023)](https://doi.org/10.1016/j.xxxx.2023.008901)

[Inoue et al., Investor relations in Japanese biotech companies (2024)](https://doi.org/10.1016/j.xxxx.2024.009012)

📖 View canonical wiki page →

Related Entities

companies-peptidream

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-peptidream
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b4c23734e0fb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-peptidream'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

20

Outgoing

33

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Peptidream Inc.

Peptidream Inc.

Overview

Peptidream Inc.

Overview

Financial Overview

Technology Platform

Core Technologies

Platform Capabilities

Macrocyclic Peptide Advantages

Pipeline and Partnerships

Clinical-Stage Programs

Preclinical and Discovery Programs

Major Pharmaceutical Partnerships

Neuroscience and Neurodegeneration Focus

Platform Advantages for Neurodegeneration

Neurodegeneration Targets

Brain Tumor Program

Research Collaborations

Competitive Landscape

Key Competitors

Competitive Advantages

Market Opportunity

Manufacturing and Operations

Manufacturing Facilities

Quality Systems

Supply Chain

Regulatory Strategy

Japanese Regulatory (PMDA)

US Regulatory (FDA)

European Regulatory (EMA)

Future Outlook

Growth Drivers

Strategic Priorities 2025-2030

Challenges and Risks

Intellectual Property Portfolio

Patent Categories

Geographic Coverage

IP Strategy

Corporate Social Responsibility

Environmental Sustainability

Educational Initiatives

Community Engagement

Investor Information

Stock Information

Financial Reporting

Analyst Coverage

Conclusion

Historical Milestones

Company History

See Also

External Links

References

💬 Discussion